AUM Biosciences and Asymchem Complete Phase II API Production Campaign of Novel TRK Inhibitor
prnewswire.com
news
2022-10-20 12:30:00

TEDA TIANJIN, P.R. China and SINGAPORE, Oct. 20, 2022 /PRNewswire/ -- Asymchem (stock code: 002821.SZ), a leading global contract development and manufacturing service provider, and AUM Biosciences (AUM), a global clinical stage biotech company, focused on discovering, acquiring and developing next generation targeted oncology therapeutics, jointly announced today the completion of their first GMP production campaign of AUM601.
Earlier this year, Asymchem and AUM Biosciences announced the two companies would collaborate on process development and clinical and commercial production of AUM 601, a highly selective oral small molecule inhibitor of the tropomyosin receptor kinase (TRK) for treating rare cancers.
